Cutaneous squamous cell carcinoma (SCC) is a common type of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin — the horny protein that makes up skin, hair and nails.

Cutaneous SCC is an invasive disease, referring to cancer cells that have grown beyond the epidermis. SCC can sometimes metastasise and may prove fatal.

Intraepidermal carcinoma (cutaneous SCC in situ) and mucosal SCC are considered elsewhere.

More than 90% of cases of SCC are associated with numerous DNA mutations in multiple somatic genes.  Mutations in the p53 tumour suppressor gene are caused by exposure to ultraviolet radiation (UV), especially UVB (known as signature 7). Other signature mutations relate to cigarette smoking, ageing and immune suppression (eg, to drugs such as azathioprine). Mutations in signalling pathways affect the epidermal growth factor receptor, RAS, Fyn, and p16INK4a signalling.

Beta-genus human papillomaviruses (wart virus) are thought to play a role in SCC arising in immune-suppressed populations. β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38 have also been associated with an increased risk of cutaneous SCC in immunocompetent individuals.

Cutaneous SCCs present as enlarging scaly or crusted lumps. They usually arise within pre-existing actinic keratosis or intraepidermal carcinoma.

• They grow over weeks to months
• They may ulcerate
• They are often tender or painful
• Located on sun-exposed sites, particularly the face, lips, ears, hands, forearms and lower legs
• Size varies from a few millimetres to several centimetres in diameter.

Feel free to share your research work on related topics in Journal of Orthopedic Oncology which offers information in all aspects of primary, malignant tumors. Osteosarcoma, Ewing's sarcoma, chondrosarcoma, chordoma, and soft tissue sarcomas etc., it also deals with diagnostic methods, therapeutic approaches, clinical, laboratory research and reconstructive techniques.

Journal uses Editorial Tracking System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Orthopedics & Oncology or outside experts; at least two independent reviewer’s approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system.

Journal Considers Research article, Review articles, editorial, letter, case reports, short communications, original articles from leading scientists and scholars around the world in all areas of related to Malignantosteoid, Multilobular tumour of bone, Chondrosarcoma, Chordoma, Osteosarcoma, Ewing's sarcomaetc., which come under the scope of the journal.

You may submit your manuscript as an e-mail attachment to the Editorial Office at  orthooncol@scholarlymed.com; joo@jpeerreview.org

Regards,

Stella

Editorial Team

Journal of Orthopedic Oncology